Post-earnings recap
Reported
Thu, Jul 30, 2026
EPS actual
$-1.99
EPS est.
$-2.55
EPS surprise
+22.02%
1-day move
-9.83%
Madrigal Pharmaceuticals reported a larger-than-expected loss per share, which contributed to a significant decline in the stock price by nearly 10%. The lack of revenue figures and guidance may have raised concerns among investors about the company's financial health and future prospects. Overall, the disappointing EPS result seems to have overshadowed any potential positives.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.99 | $-1.12 | +22.02% |
| Revenue | — | $401M | — |
No transcript is on record, and the analysis is based on numerical results only.
Madrigal Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for liver and metabolic diseases. With a market cap of $12 billion, its work is particularly relevant as the healthcare sector increasingly prioritizes treatments for chronic conditions.
Last quarter
In Q1-2026, Madrigal reported an EPS of $-3.25, which was better than analysts' expectations of $-3.61, resulting in a positive stock reaction of +7.42% the following day. However, revenue details were not disclosed.
EPS beat streak
2Q
EPS beat rate
75%
Avg EPS surprise
-930.87%
Avg 1-day reaction
+4.52%
Analysts expect Madrigal to report a narrower loss in EPS this quarter, with revenue estimates suggesting a solid performance. The market is closely watching how the company manages its costs and sales.
Bull case
If Madrigal can exceed the revenue consensus and show signs of improving profitability, it could lead to a significant positive reaction in the stock price.
Bear case
On the other hand, if the company fails to meet revenue expectations or reports a larger loss than anticipated, it could lead to a sharp decline in stock value.
Key metrics to watch
EPS
$-1.12Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$401MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will Madrigal report revenue above the consensus estimate of $401 million?
Exceeding this revenue target would indicate strong demand for its products and could boost investor confidence.
Q2
How will the company address its EPS loss of $-1.12?
Investors will be looking for clarity on cost management and any strategies to improve profitability moving forward.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±13.6%
Why consensus could be wrong
The Street may underestimate Madrigal's ability to improve its EPS loss due to recent operational efficiencies that have not been fully recognized.
Supporting evidence
Madrigal has a history of beating EPS estimates, with a 75% success rate in recent quarters.
The options market is pricing in a significant move, suggesting that traders expect a surprise in either direction.
Key risk
If revenue comes in below $385 million, it could undermine the positive sentiment surrounding the stock.
Pre-commit to what would confirm each case.
The market is debating whether Madrigal can turn its financial performance around, especially in light of its recent earnings history.
Bull confirmed if
Revenue exceeding $401 million with a narrower EPS loss than $-1.12 would confirm the bull case.
Bear confirmed if
An EPS loss greater than $-1.12 and revenue falling below $385 million would support the bear case.
What the market is pricing for the move.
Implied Move
±25.88%
Historical Avg
±10.2%
The options market is pricing in a significant move, indicating that investors expect volatility around the earnings report.
Options are pricing ±25.9% while MDGL has averaged ±10.2% over the last 8 prints — setup is pricing rich.
ATM IV
0.5%
30d HV
37.7%
Smart-money positioning from the most recent 13F filings.
Institutional
104.65%
of float
Insider
5.83%
of float
Holders
562
institutions
Top Holders· as of Jun 2026
Baker Bros. Advisors, LP
2,143,131 sh · $1.0B
9.28%
0.1%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Madrigal beats expectations, history suggests the stock could rise by around +6.18%, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may react moderately, reflecting cautious sentiment from investors.
Miss
A miss on earnings could lead to a decline of about -1.64%, as seen in past quarters.
The lines on the call that would change the story.
RTW Investments LP
1,993,687 sh · $972.4M
8.63%
Flat
Jupiter Topco LLC
1,936,099 sh · $944.3M
8.38%
100.0%
Avoro Capital Advisors LLC
1,833,333 sh · $894.2M
7.94%
0.8%
PAULSON & CO. INC.
1,340,020 sh · $653.6M
5.80%
-3.8%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.